MD
Research & Clinical Trials59 Assigned Reports
Marc Dubois
Science & Clinical Trials Correspondent • Lead Science Editor
Marc investigates preclinical pharmacology, mass spectrometry verification, peptide purity assays, and the translation of experimental multi-receptor agonists into clinical endpoints.
This is an editorial voice and assignment profile, not a verified individual journalist biography. Published work is attributed to the Peptides Agora Editorial Desk unless a verified human author is named.
Focus Beats:Clinical TrialsHPLC TestingPeptide SynthesisAnalytical ChemistryCOA VerificationMetabolic Agonists
Articles assigned to the Marc Dubois voice
Showing 59 reports
clinical-trials•
Teitur's First-In-Class Parkinson's Peptide Clears Phase 1
clinical-evidence•
Clinical Evidence Quality for Topical Cosmetic Peptides
research-peptide-market•
Integrity Research Peptides: Analytical Scope and Evidence Limits
clinical-evidence-and-uses•
How Long Does Mounjaro Take To Work: Tirzepatide Onset Timelines
regenerative-immunology•
BPC-157 in IBD: Preclinical Repair Mechanisms Versus Absent Human Efficacy Data
cyclic-antimicrobial•
Cyclic Antimicrobial Peptide Pharmacology: LPS Binding Versus Renal Uptake
antimicrobial-peptides•
Histatin Mechanisms in Oral Wound Closure and Candida Defense
antimicrobial-peptides•
Human Beta-Defensin Immunology: Structural Stability, MIC Data, and Barrier Limits
melanocortin-fragments•
KPV Mechanism Relies on PepT1 Transport and NF-κB Inhibition in Murine Colitis Models
vaccines-and-oncology•
Neoantigen Peptide Vaccines: Prediction Accuracy Versus Clinical T-Cell Expansion
melanocortin-agonists•
Bremelanotide Clinical Pharmacology: MC4R Agonism and RECONNECT Trial Outcomes in HSDD
targeted-metabolic•
AOD-9604 and PT-141: Divergent Lipolytic Mechanisms in Human Adipose Tissue
incretin-deep-dives•
Tirzepatide Dual Agonism: SURMOUNT Efficacy Data and Pharmacological Mechanisms
phagocytosis-peptides•
Tuftsin Macrophage Activation: Neuropilin-1 Kinetics vs Clinical Efficacy
gastric-and-angiogenesis•
BPC-157 Pharmacology: Salt Stability, VEGFR2 Signaling, and the Clinical Evidence Gap
telomerase-and-circadian•
Epitalon Telomerase Claims Rest on Single-Lab In Vitro Data and Unreplicated Cohorts
dermal-and-remodeling•
GHK-Cu Evidence Base: Fibroblast Assays, Gene Profiling, and Clinical Limits
mitochondrial-peptides•
MOTS-c Mechanism and Evidence Gaps: From Mitochondrial ORF to Preclinical AMPK Activation
quality-and-sourcing•
Research Peptide Quality Is Defined by Batch Documentation, Not Purity Claims
nootropics-and-bdnf•
Semax Pharmacology: BDNF Upregulation Evidence Versus Regulatory Divergence
cellular-migration•
TB-500 Fragment Versus Thymosin Beta-4: Actin Mechanisms and Evidence Gaps
clinical-trials-and-efficacy•
Phase 3 Readouts Define Weight Loss Peptide Efficacy and Body Composition Trade-offs
synthesis-and-manufacturing•
Custom Peptide Synthesis: Process and Quality Controls
research-peptide-market•
"Research Use Only" Labels Cannot Substitute for GMP Standards in the Peptide Market
purity-and-coa•
Decoding Purity Claims in Research Peptide COAs
formulations-and-delivery•
Why Oral Peptides Are Hard to Deliver
analytical-testing•
Peptide Testing: Identity, Purity, and Analytical Limits
research-peptide-market•
Research Peptides: Regulatory Status, Analytical Verification, and Lab Integrity
metabolic-health•
Weight Loss Peptides: FDA Approval vs. Experimental Status
definitions-and-types•
What Are Peptides? Structure, Types, and Uses
general-peptide-topics•
Wolverine Stack Surge: Clinics Push BPC-157 and TB-500 Blend Amid Regulatory Gaps
research•
